Literature DB >> 2752502

Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.

U Tidefelt1, B Sundman-Engberg, C Paul.   

Abstract

A direct comparison of the intracellular pharmacokinetics of 4'-epi-doxorubicin and doxorubicin was carried out in five patients with leukemia who were given weekly low doses of a combination of these drugs at 20 mg each in an i.v. injection. Blood samples were collected for 48 h after administration and the drug concentrations in leukemic cells were determined by high-performance liquid chromatography (HPLC). The intracellular peak concentrations of 4'-epi-doxorubicin were higher than those of doxorubicin in all patients. The AUC for the intracellular drug concentration vs time curve was significantly higher for 4'-epi-doxorubicin. The intracellular uptake and retention were also studied in vitro after incubation of isolated leukemic blast cells with the two drugs; they showed the same pattern observed in vivo. We conclude that 4'-epi-doxorubicin and doxorubicin exhibit different pharmacokinetics in malignant cells. The therapeutic significance of this finding requires further evaluation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752502     DOI: 10.1007/bf00257622

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

Authors:  S Eksborg; U Stendahl; U Lönroth
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

Authors:  C M Camaggi; E Strocchi; V Tamassia; A Martoni; M Giovannini; G Lafelice; N Canova; D Marraro; A Martini; F Pannuti
Journal:  Cancer Treat Rep       Date:  1982-10

3.  Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin.

Authors:  B Andersson; M Beran; C Peterson; B Tribukait
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

4.  Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.

Authors:  A Di Marco; A M Casazza; T Dasdia; A Necco; G Pratesi; P Rivolta; A Velcich; A Zaccara; F Zunino
Journal:  Chem Biol Interact       Date:  1977-12       Impact factor: 5.192

5.  Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents.

Authors:  H S Schwartz; P M Kanter
Journal:  Cancer Treat Rep       Date:  1979-05

6.  Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.

Authors:  C Paul; C Peterson; G Gahrton; D Lockner
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  A phase II study of epirubicin in acute leukemia: a cooperative group study.

Authors:  K Sampi; T Masaoka; S Shirakawa; T Shirai; T Abe; H Shibata; M Umeda; T Kobayashi; H Sugiyama; H Toki
Journal:  Anticancer Res       Date:  1987 Jan-Feb       Impact factor: 2.480

8.  Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer.

Authors:  C Peterson; P Gunvén; N O Theve
Journal:  Cancer Treat Rep       Date:  1986-08

9.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

10.  Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.

Authors:  C Paul; R Baurain; G Gahrton; C Peterson
Journal:  Cancer Lett       Date:  1980-06       Impact factor: 8.679

View more
  3 in total

1.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

Authors:  M Bakker; J P Droz; A R Hanauske; J Verweij; A T van Oosterom; H J Groen; M A Pacciarini; L Domenigoni; F van Weissenbruch; E Pianezzola; E G de Vries
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.